When: Price above $276.88 with volume >7M and MACD bullish re-cross

Then: Confirm momentum-confirmed upside for re-engagement

HOLD existing position; do not add at current levels; collect dividend and wait for better entry

• Current trailing P/E of 31x versus 5-year average in low-to-mid twenties leaves multiple compression risk of ~20%
• Consensus forward EPS of $12.14 would only justify $267 at 22x multiple—below current $269.47 price with zero margin of safety
• Trailing five quarters essentially flat: $2.29, $2.12, $2.10, $2.14, $2.27
• If JNJ delivers 'half' the consensus growth, EPS of $10.37 at 25x multiple = $259, below current price
• Q1 2026 net debt jumped to $33.3 billion before deleveraging in Q2
• Caplyta approval should be treated as 60% probability, not base case; DePuy $20B divestiture is M&A optionality until signed
• Downside scenario: $10 EPS at 20x multiple = $200, or 200-day MA at $236.85 (12% drawdown vs ~0% upside)
• 90-day return of 18% makes JNJ one of the most extended defensive names in healthcare
• Existing position generates approximately 2% dividend yield while waiting
• Technical setup shows MACD bearish cross, 10 EMA declining, price below VWMA, volume 4.22M vs 6-7M average

→ vs aggressive: AAA premium as floor argument ignores that JNJ traded at high teens P/E in the last decade; multiple compression to 22x with even modest EPS revision = 20% drawdown without credit event

→ vs aggressive: Forward EPS of $12.14 is consensus analyst forecast, not market pricing; trailing five quarters show EPS essentially flat, making $12.14 a best-case assumption not a base case

→ vs aggressive: 96% probability of zero Fed cuts signals sticky inflation and elevated discount rates—bearish for equity multiples, not bullish; 'no-cut' regime is not 'goldilocks'

→ vs aggressive: Caplyta and DePuy catalysts treated as already in the bag; approval should be 60% probability, divestiture is M&A optionality until signed term sheet

→ vs aggressive: Technical RSI reset argument ignores MACD bearish cross, declining 10 EMA, price below VWMA, and declining volume—picking optimistic interpretation as fact

→ vs aggressive: Bear case math ($10.37 EPS at 25x = $259) is below current price, undermining the bull thesis; market already pricing in execution

→ vs aggressive: 0.235 beta protects against market risk but not idiosyncratic risks: talc litigation, opioid obligations, Stelara biosimilar erosion, and net debt of $33.3B in Q1 2026

→ vs aggressive: 'Never get the pullback' argument ignores downside catalysts: Caplyta delay, DePuy falling through, Stelara acceleration—FOMO dressed as analysis

HOLD at 5-8% core position (upper bound refined to 8-10%); add zone at $262-265 on confirmed 50 SMA defense; stop at $262.75; breakout watch at $276.88 with volume above 7 million shares and MACD bullish re-cross to consider adding on pullback

• Forward EPS of $12.14 is a 12-to-24-month consensus forecast, not near-term reality; trailing five quarters ($2.29, $2.12, $2.10, $2.14, $2.27) annualize to roughly $8.60-$8.80, aligning with TTM EPS of $8.61
• Aggressive analyst's $259 target ($10.37 EPS at 25x multiple) shows market paying full forward multiple with minimal execution margin
• Macro signal of '96% odds of no Fed cuts' is genuinely neutral for JNJ—neither the tailwind the aggressive wants nor the headwind the conservative fears
• Caplyta and DePuy are real catalysts with low-to-moderate probability and 6-to-18 month timeline (Caplyta expansion likely 2027, not 2026)
• RSI reset from 74 to 54 without price pullback is unusual—a divergence in time domain that more consistently supports the conservative 'buyers losing conviction at the highs' read
• Technical deterioration: MACD bearish cross, 10 EMA rolling over, price below VWMA, declining volume at recent highs
• Conservative's $200 bear case requires simultaneous 18% forward EPS miss AND multiple compression to 2014 levels—stacked pessimistic assumptions that rarely coincide
• Conservative's $236 bear case at 200-day MA requires both 18% EPS miss and 19.5x multiple compression—probabilistically too pessimistic
• JNJ's historical pullback behavior means waiting for $239 is probably a losing strategy; 'wait for deep pullback' framework has low hit rate on this name
• 0.235 beta provides genuine defensive diversification benefit warranting 8-10% allocation (not just 5-8% floor)
• Macro gap: rates, inflation, employment, and yield curve data unconfirmed—bias toward conservative sizing until macro picture clarifies
• Q2 2026 revenue acceleration at 6.6% YoY is strongest in five quarters, contradicting 'flat-to-down' narrative
• Forward multiple framework tells different story than trailing P/E alone; aggressive is wrong to dismiss it
• Earnings misses and multiple compressions tend to mean-revert separately in large-cap pharma; rarely coincide at extreme levels

→ vs aggressive: Treats $12.14 forward EPS as near-term reality rather than 12-to-24-month consensus forecast; the $259 target ($10.37 EPS at 25x multiple) shows full forward multiple with no execution margin—that's thin margin of safety, not bullish asymmetry

→ vs aggressive: Macro '96% odds of no cuts' interpretation flatters the thesis; same signal also indicates sticky inflation, persistent cost pressure, and economic resilience that can compress multiples on quality names—the conservative read sits equally valid in the same data

→ vs aggressive: Caplyta and DePuy catalysts are real but not imminent; Caplyta timeline is likely 2027, not 2026, and DePuy is multi-year optionality—correct that they're not speculative but wrong that they're near-term

→ vs aggressive: RSI interpretation as 'healthy reset clearing the way' misses that RSI reset without corresponding price pullback is unusual; price-RSI divergence makes the conservative read more internally consistent with the actual data

→ vs aggressive: Dismisses MACD bearish cross, 10 EMA rolling over, price below VWMA, and declining volume as 'prior-matching'—but these aren't noise, they signal marginal buyers stepping away

→ vs aggressive: Pushes for sizing up to 12-15% without confirmed breakout trigger; wrong given unresolved technical deterioration and macro gap

→ vs conservative: $200 bear case requires simultaneous 18% forward EPS miss AND multiple compression to levels not seen since 2014—coordinated pessimistic outcome that is internally consistent but probabilistically too pessimistic

→ vs conservative: Dismisses 'wait for $239' rebuttal without substantive engagement; if JNJ has had exactly one meaningful pullback to 200-day MA in the entire run, that framework has low historical hit rate and isn't actionable

→ vs conservative: 'Wait for deep pullback' framework is too patient for JNJ's specific trading character; should set buy zone at $262-265, not wait for $250-255 or $239

→ vs conservative: Anchors valuation fears on trailing P/E alone while ignoring that forward multiple framework tells a different story than the conservative framing suggests

→ vs conservative: Overstates bear scenario magnitude; historical record for large-cap pharma suggests earnings misses and multiple compressions rarely coincide at extreme levels, they mean-revert separately

→ vs conservative: Correctly identified FRED macro data gap but neither aggressive nor conservative dealt with it substantively; incomplete information warrants bias toward conservative sizing